Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.
Synlogic has raised $21.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in September 2023.
Synlogic's investors include Bill & Melinda Gates Foundation, New Enterprise Associates, Perceptive Advisors, OrbiMed, Ginkgo Bioworks.
Synlogic is headquartered in Cambridge, United States.
Synlogic is a biotechnology company that develops synthetic biotic medicines to perform metabolic functions to treat diseases.
Synlogic is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Synlogic — Funding & Investors." VCBacked, September 29, 2023, https://www.vcbacked.co/company/synlogic. Accessed July 21, 2026.
VCBacked. (2023). Synlogic — Funding & Investors. Retrieved July 21, 2026, from https://www.vcbacked.co/company/synlogic
{{cite web |title=Synlogic — Funding & Investors |url=https://www.vcbacked.co/company/synlogic |website=VCBacked |access-date=July 21, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated